Form 4: Bionano Genomics Director Aleksandar Rajkovic Granted Stock Options

Bionano Genomics, Inc. has reported that Director Aleksandar Rajkovic was granted 2,775 stock options with an exercise price of $3.67 per share, vesting over 12 months.

Summary

• Aleksandar Rajkovic, a Director of Bionano Genomics, Inc. (BNGO), was granted 2,775 stock options.
• The transaction date for this grant was June 11, 2025.
• Each stock option has an exercise price of $3.67.
• The options will vest in equal monthly installments over 12 months from the grant date, or fully vest on the date of the Company's next annual stockholder meeting, whichever comes first, subject to continuous service.
• Full vesting will also occur upon a Change of Control, as defined in the Company's 2018 equity incentive plan.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Aleksandar Rajkovic beneficially owns 2,775 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation disclosure that aligns director interests with shareholders, which is generally viewed favorably, but it does not indicate any new operational or financial performance.

Positives

• The grant of stock options aligns the interests of Director Aleksandar Rajkovic with those of the shareholders, as the value of the options is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The stock options are subject to a vesting schedule, with shares vesting in equal monthly installments over 12 months or fully vesting by the next annual stockholder meeting, contingent on the option holder's continuous service. Full vesting will also occur upon a Change of Control.

Industry Context

The grant of stock options to a director is a common form of equity compensation across various industries, including biotechnology and genomics, aimed at aligning the interests of board members with long-term shareholder value creation.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a standard practice for compensating non-employee directors in publicly traded companies across most sectors, including life sciences and technology.
• The vesting schedule (12 months or next annual meeting) is a typical short-to-medium term vesting period for director grants, designed to encourage continued service and commitment.
• The inclusion of a 'Change of Control' acceleration clause is also standard in many equity incentive plans, providing protection and incentive for directors during corporate transitions.

Related Party Transactions

• The grant of stock options to Director Aleksandar Rajkovic constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will begin their vesting schedule, with shares vesting monthly over 12 months or fully by the next annual stockholder meeting.
• The option holder must maintain Continuous Service with the company to continue vesting.

Key Dates

Keywords

Bionano Genomics, BNGO, Stock Option, Equity Grant, Director Compensation, SEC Form 4, Insider Transaction, Executive Compensation